FDA
-
-
-
-
-
-
-
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Appr
-
-
-
-
-
-
-
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
-
-
-
-
-
-
-
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (AS
-
-
-
-
-
-
-
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
-
-
-
-
-
-
-
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
PDS Biotechnology (PDSB) Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
-
-
-
-
-
-
-
PDS Biotechnology (PDSB) Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO
-
322,220 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

